testicular cancer
Conditions
Interventions
The number of circulating endothelial cells, endothelial marker proteins and accumulation of AGEs (estimated by measuring skin autofluorescence with an AGE-reader) will be determined before, during an
Sponsors
Department of Internal Medicine: Division of Medical Oncology, University Medical Center Groningen (UMCG)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with disseminated testicular cancer who will be treated with cisplatin based chemotherapy; 2. Age 18-50 years at start of treatment; 3. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Medical history of cardiovascular disease; 2. Known renal disease or estimated glomerular filtration rate (GFR) < 60 ml/min (using Cockcroft-Gault formula).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The early effects of cisplatin based chemotherapy on the number of circulating endothelial (progenitor) cells and the accumulation of AGEs, and their correlation with cardiovascular damage. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Evaluation of which treatment and patient related factors (for example chemotherapy dose and presence of cardiovascular risk factors) predispose to cardiovascular damage during and after cisplatin based chemotherapy; 2. Determination of circulating apoptosis markers during and after cisplatin based chemotherapy and their relation to tumor response and cardiovascular damage. | — |
Contacts
Public ContactE.C. Haas de
Medische Oncologie, Universitair Medisch Centrum Groningen, Hanzeplein 1
Outcome results
None listed